Victor Bartsevich

This inventor holds 20 USPTO granted patents and 28 published patent applications and 11 EPO patents. Top assignee: Precision Biosciences, Inc.. Active years: 2018-2026.

USPTO Granted Patents = 20 (Patent Applications = 28)

% Patents Active = 100.0

EPO Patents = 11 (Patent Applications = 19)

Average Co-Inventor Count = 5.1

ph-index = 8

Forward Citations = 165(Granted Patents)

Company Filing History:

20 out of 54

Precision Biosciences, Inc.

patents

Years Active: 2018-2026

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595470 - ENGINEERED NUCLEASES THAT TARGET HUMAN AND CANINE FACTOR VIII GENES AS A TREATMENT FOR HEMOPHILIA A (2026-04-07),

2. 12595469 - TREATMENT OF RETINITIS PIGMENTOSA USING IMPROVED ENGINEERED MEGANUCLEASES (2026-04-07),

3. 11788077 - Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome (2023-10-17),

4. 11680254 - Engineered meganucleases specific for recognition sequences in the PCSK9 gene (2023-06-20),

5. 11278632 - Engineered nucleases useful for treatment of hemophilia A (2022-03-22),

6. 11268065 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2022-03-08),

7. 11266693 - Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene (2022-03-08),

8. 11142750 - Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome (2021-10-12),

9. 10799535 - Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene (2020-10-13),

10. 10758595 - Treatment of retinitis pigmentosa using engineered meganucleases (2020-09-01),

11. 10603363 - Treatment of retinitis pigmentosa using engineered meganucleases (2020-03-31),

12. 10093900 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-10-09),

13. 10093899 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-10-09),

14. 9993502 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-06-12),

15. 9993501 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-06-12),

Title: Victor Bartsevich: Pioneering Inventor from Durham

Introduction: Victor Bartsevich is a renowned inventor based in Durham, NC, known for his groundbreaking contributions to various fields.

Latest Patents: Victor Bartsevich holds several patents in the areas of technology, healthcare, and consumer products, with his most recent inventions focusing on sustainable energy solutions.

Career Highlights: Throughout his illustrious career, Victor Bartsevich has been recognized for his innovative spirit and problem-solving abilities, leading to the development of cutting-edge technologies that have revolutionized industries.

Collaborations: Victor Bartsevich has collaborated with leading research institutions, universities, and companies to bring his inventions to life, showcasing his ability to work across disciplines and sectors.

Conclusion: Victor Bartsevich's dedication to innovation and his passion for creating impactful solutions have solidified his reputation as a trailblazing inventor in Durham and beyond.